Research
Hormonal
GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE), death, and stroke in patients with type 2 diabetes.
If you have type 2 diabetes, GLP-1 receptor agonists can significantly lower your risk of heart attacks, strokes, and death. This benefit is independent of weight loss and is supported by large-scale data involving over 60,000 patients.
StrongSupportsVERY_HIGH confidence
a recent meta-analysis assessing CV outcome of different GLP-1R agonists across eight CV outcome trials comprising 60,080 patients with T2D. It demonstrated that GLP-1R agonists reduce the risk of a major adverse cardiovascular event (MACE) by 14%, death by 13%, non-fatal stroke by 12%, and broad composite kidney outcome by 17% (144).
Why this rating
Based on a meta-analysis of 8 trials with >60,000 patients.
Source
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan et al. · Frontiers in Endocrinology · 2022
DOI 10.3389/fendo.2022.838410
narrative_reviewCited 142×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4 mg administered once weekly induces significant body weight reduction (>10% in ~69% of patients) in non-diabetic adults with obesity when used as an adjunct to lifestyle programs.Strong
- Tirzepatide, a dual agonist of GLP-1 and GIP receptors, achieves significant body weight and glucose control in patients with obesity and type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →